Objective. The aim of this study is to evaluate the mechanism of long-term effect of autologous haematopoietic stem cell transplantation (ASCT) in treatment of SSc.
Introduction
SSc is a heterogeneous autoimmune disease (AD) characterized by predominant T-cell activation, production of auto-antibodies and cytokine release [1, 2] . All of these contribute to diffuse microvascular injury, leading to diffuse sclerosis within the skin and internal organs. DcSSc and internal organ involvement often cause lifethreatening status of patients [3] .
Autologous haematopoietic stem cell transplantation (ASCT) was introduced for SSc treatment in 1996, and >100 patients with SSc have been treated [4] . Phase III studies demonstrated that improvement of skin sclerosis and stabilization of interstitial pneumonia (IP) were achieved [510] . We also reported the safety and efficacy of high-dose CYC with ASCT for SSc patients [11] . The complete or partial remission of SSc was maintained for at least 3 years in these reports [69] .
The working hypotheses of the efficacy of ASCT for SSc might be due to the immune reset that should include: (i) the eradication of auto-reactive lymphocytes by immunoablative conditioning; and/or (ii) the correction of dysregulated immune balance by newly developed lymphocytes derived from transplanted haematopoietic stem cells [12] . However, there remains controversy regarding whether such immune reset occurs in patients treated with ASCT. Muraro et al. [13] have reported that naïve CD4
+ T cells with diverse T-cell receptor repertoire, which were generated through thymus, developed after ASCT in patients with multiple sclerosis (MS). In contrast, in SSc patients, Farge et al. [14] reported the sustained reduction of CD4 + T cells and B cells after ASCT.
Furthermore, Th1/Th2 balance might also be important in understanding the disease status of SSc. In a tight skin mouse, an animal model for SSc, the stimulation of Th1 immune responses prevents the development of scleroderma-like syndrome [15] . In human SSc, a shift from Th2 to Th1 responses is correlated with improvement of the skin fibrosis by longitudinal analysis of serum cytokine concentrations [16] .
These data led us to analyse immune reconstitution in SSc patients treated with ASCT. In this study, we tracked reconstitution of T-and B-cell subpopulations after ASCT with purified CD34 + haematopoietic stem/progenitor cells in SSc patients, and found that despite the resolution of clinical symptoms of SSc, patients did not achieve normalization of lymphocyte compartment, even 3 years after ASCT. All patients showed sustained reduction of CD4 T cells, but Th1/Th2 ratio was increased during the 3-year observation. Thus, the clinical efficacy of ASCT might be dependent upon the skewed reconstitution of Th1 cells for a long time after ASCT.
Patients and methods
The study was approved by the ethics committee of Kyushu University Hospital. Written informed consent was obtained from all patients according to the Declaration of Helsinki.
Patients and eligibility
Eligibility of patients with SSc for ASCT was previously described [11] . Briefly, patients with SSc were eligible when they had severe diffuse SSc that had rapidly developed over the previous 4 years. They also had to have at least one of the following organ involvements: (i) pulmonary, (ii) cardiac or (iii) renal involvement. Patients with limited SSc were considered eligible when progressive and life-threatening IP was present. Patients were excluded from the study when they had uncontrolled arrhythmia, severe heart failure, pulmonary hypertension, DL CO <20% of predicted and renal failure as previously described [11] . All patients were followed up for at least 36 months after transplantation for the evaluation of immune reconstitution. Blood was obtained from healthy donors (after informed consent, n = 10) to determine the reference values of lymphocyte subpopulations and Th1/Th2 balance, and from SSc patients (after informed consent, n = 13) for FoxP3 staining.
Peripheral blood stem cell collection and ASCT Peripheral blood stem cells (PBSCs) were mobilized during haematologic recovery after relatively high-dose CYC (2 g/m 2 ) for 2 days followed by administration of recombinant human G-CSF (filgrastim; Kirin Brewery, Tokyo, Japan) as previously described Table 1) . The anti-Scl-70 antibody, an auto-antibody specific to diffuse SSc, was detected in 9 out of 11 patients. All patients were resistant to the standard treatment with CS, CYC and/or ciclosporin. Blood mononuclear cells were harvested after mobilization with CYC and G-CSF. CD34
+ haematopoietic stem/ progenitor cell fractions were purified and cryopreserved. Patients were transplanted with purified autologous CD34 + cells after high-dose CYC (500 mg/kg) conditioning. Consequentially, 4.7 Â 10 6 /kg CD34 + cells with 1.1 (1.2) Â 10 4 /kg CD3 + T-cell contaminants were transplanted. ASCT was successfully performed without transplantation-related mortality in all patients, but Patient 7 died due to the progression of IP at 20 months after ASCT. The clinical status of the remaining 10 patients was followed up for >36 months. There was a variety of post-transplant infections such as adenoviral haemorrhagic cystitis, herpes zoster and cytomegaloviral antigenaemia [18] .
CD34 + ASCT treatment induced resolution of refractory SSc
The effect of ASCT on skin sclerosis was assessed by the change in mRSS. After ASCT, skin sclerosis was progressively resolved, and had improved by 72.0% at 36 months post-transplant (Fig. 1A) . The vital capacity of the lung was increased from 64.9 to 77.8% at 36 months, although DL CO was unchanged (Fig. 1B) . Serum levels of KL-6 and SP-D, indicators of IP activity [19, 20] , were significantly decreased ( Fig. 1C and D) . Reflecting the resolution of clinical symptoms of SSc, the serum level of anti-Scl-70 progressively decreased after ASCT ( Fig. 2A) , independent of serum immunoglobulin levels (Fig. 2B) . A significant correlation (r = 0.52, P < 0.05) was observed between the change in mRSS and that in the serum level of anti-Scl-70 at 36 months after ASCT.
Serum levels of pro-inflammatory or pro-fibrotic cytokines and a T-cell activation marker such as TNF-a, TGF-b, IL-6 and soluble IL-2R (sIL-2R), were also decreased after ASCT (Fig. 3AD) . These data show that ASCT with purified CD34 + cells is effective in controlling disease activity of SSc patients refractory to conventional immunosuppressive therapies. www.rheumatology.oxfordjournals.org
Th1 CD4 + T cells after autologous HSCT for SSc
To study whether correction of abnormalities in functional subsets of B cells was associated with durable remission, we focused on the functional subset of CD19 + B cells. The number of CD19 + CD27 + memory B cells was low at baseline, which was characteristic of SSc [23] . An increase in the number of memory B cells, however, was not observed even at 36 months after ASCT, and the vast majority of recovered B cells were naïve CD19 + CD27 À B cells (Fig. 4D ).
Th1 CD4 + T cells were predominantly reconstituted after CD34
+ ASCT Previous data showed that Th1/Th2 balance was associated with skin sclerosis in an animal model of SSc [15] . Therefore, we analysed Th1/Th2 balance after ASCT by measuring the ratio of intracellular IFN-g increased at 1 month and reached a plateau at 6 months after ASCT (Fig. 5B) . The skewed reconstitution of Th1 CD4 + T cells was maintained for 36 months after HSCT.
There were no significant correlations between the changes in mRSS and those in Th1/Th2 balance.
Discussion
In this study, the resolution of disease was progressively obtained in SSc patients for 36 months after ASCT. This durable effect was not due to the reconstitution of naïve CD4 + T cells, regulatory T cells or the correction of B-cell imbalance. On the other hand, the elimination of Th2 cells by high-dose CYC as well as the predominant reconstitution of Th1 cells were observed after ASCT. Reflecting the resolution of clinical symptoms of SSc, serum levels of anti-Scl-70 progressively decreased after ASCT. Serum levels of KL-6 and SP-D, indicators for IP activity, were also significantly decreased. In patients with SSc, production levels of type 2 cytokines such as IL-4, IL-6 and IL-13 by stimulated peripheral blood mononuclear cells and cultured CD4 + T cells decreased [24, 25] . Our data showed that the ratio of IFN-g-to IL-4-producing CD4 + T cells was significantly increased in a month and was sustained for 36 months after ASCT. The predominant reconstitution of IFN-gproducing cells is associated with amelioration of skin sclerosis, probably due to an ability of IFN-g to reduce excessive collagen synthesis by scleroderma-derived fibroblasts [26] . IL-4 increases collagen production of fibroblasts and induces the production of TGF-b in patients with SSc [27] . Therefore, the elimination of IL-4-producing T cells provides a favourable effect on SSc. The limitation of this study was small sample size and that there were not significant correlations between the changes in mRSS and those in Th1/Th2 balance. It is unclear how predominant reconstitution of Th1 CD4 + T cells after ASCT is induced. Polarization of CD4 + T cells after ASCT may depend on the local levels of cytokines such as IL-12 or IL-4 when naïve CD4 + T cells develop into functional T cells [28] . Predominant reconstitution of Th1 CD4 + T cells after ASCT may also occur in patients with other autoimmune diseases when treated by ASCT. Therefore, it is conceivable that ASCT is potently effective for Th2-related diseases such as SSc and SLE, while its effect on Th1-related diseases such as RA is limited [4] . Macrophage activation syndrome is often observed in patients with JIA after ASCT [29] . It may be associated with a Th1 immune response after ASCT. Our data showed that despite the resolution of clinical symptoms of SSc, patients did not achieve normalization of lymphocyte compartment, even 3 years after ASCT. (Fig. 4D ). In the study of Storek et al. [30] , both naïve and memory B cells recovered to the normal range in 6 months after ASCT. Collectively, the resolution of clinical SSc after ASCT was not due to the reconstitution of naïve CD4 + T cells or to that of regulatory T cells or to the correction of B-cell imbalance. An anti-Scl-70 antibody, a useful marker in establishing the diagnosis of SSc, predicts diffuse skin involvement and pulmonary fibrosis, and the increased level of this antibody is associated with a poor prognosis. In this study, we, for the first time, showed that the level of an anti-Scl-70 antibody was continuously decreased for 36 months after ASCT, and that the changes in anti-Scl-70 level were correlated significantly with those in mRSS. These results are consistent with a previous report that showed the correlation of serum anti-Scl-70 levels with disease activity in SSc [31] , although the role of anti-Scl-70 in the pathogenesis of SSc was not clearly demonstrated in this article. It is of interest that the changes in serum anti-Scl-70 levels were independent of those in serum immunoglobulin levels, which returned to the baseline level at 12 months after ASCT (Fig. 2) . In the study of Storek et al. [30] , the level of anti-Scl-70 continued to be abnormally high throughout 24 months after ASCT. This difference might come from the difference in transplant conditioning (CYC 200 vs CYC 120 mg/kg + total body irradiation 8 Gy + anti-thymocyte globulin) or in the purity of the CD34 + cells. Dysregulated cytokine production was reported in SSc patients [32, 33] . In this study, serum levels of TNF-a, TGF-b, IL-6 and sIL-2R increased before mobilization as previously reported [32] , but their levels significantly decreased after ASCT (Fig. 3) . Serum levels of VEGF and monocyte chemotactic protein 1 (MCP-1), however, did not decrease after ASCT (data not shown). The decreased levels of profibrotic cytokines after ASCT might reflect resolution of the disease.
Patient 7 died due to progressive IP in spite of the improvement of skin sclerosis at 20 months after ASCT. In this patient, IP was already highly advanced (per cent VC 39%) at the time of ASCT. Immune reconstitution after ASCT was similarly obtained in terms of Th1/Th2 balance and serum levels of pro-fibrotic cytokines. Therefore, the disease was fatal because of advanced and refractory IP that did not respond to the resolution of autoimmune reactions. This result suggests that patients with advanced organ involvement need to be excluded in a future study.
In conclusion, ASCT with purified CD34 + cells was effective in controlling the disease activity of SSc. Improvement of skin sclerosis was significantly associated with the change in serum anti-Scl-70 level after ASCT. Th1/Th2 ratio was significantly increased for at least 3 years after ASCT.
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